Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment

Blood Cancer J. 2016 Nov 11;6(11):e496. doi: 10.1038/bcj.2016.106.

Authors

S Betrian¹, L Ysebaert^{1

2}, K H Heider³, J P Delord⁴, J J Fournié¹, A Quillet-Mary¹

Affiliations

¹ CRCT, Université de Toulouse, CNRS ERL 5294, Inserm U1037, Toulouse, France.
² Department of Haematology, Institut Universitaire du Cancer, Toulouse, France.
³ Boehringer Ingelheim RCV GmbH & Co KG, Wien, Austria.
⁴ Institut Universitaire du Cancer, Bureau d'études cliniques, Toulouse, France.

No abstract available

Publication types

Clinical Trial, Phase I
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology*
Antibodies, Monoclonal, Humanized / therapeutic use
Antigens, Neoplasm / immunology*
Antineoplastic Agents, Immunological / pharmacology*
Antineoplastic Agents, Immunological / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cell Proliferation / drug effects
Drug Resistance, Neoplasm / drug effects*
Drug Synergism
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Neoplasm Recurrence, Local / drug therapy
Neoplasm Recurrence, Local / pathology
Purines / administration & dosage*
Purines / pharmacology
Quinazolinones / administration & dosage*
Quinazolinones / pharmacology
Recurrence
Tetraspanins / immunology*
Treatment Outcome
Tumor Microenvironment / drug effects

Substances

Antibodies, Monoclonal, Humanized
Antigens, Neoplasm
Antineoplastic Agents, Immunological
BI 836826
CD37 protein, human
Purines
Quinazolinones
Tetraspanins
idelalisib